Lexaria Bioscience Files 8-K
Ticker: LEXX · Form: 8-K · Filed: Mar 1, 2024
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Lexaria Bioscience filed a standard 8-K, no major news yet.
AI Summary
Lexaria Bioscience Corp. filed an 8-K on February 29, 2024, reporting other events. The filing details the company's incorporation in Nevada and provides its principal executive office address in Kelowna, BC, Canada. No specific financial transactions or material events are detailed in the provided excerpt.
Why It Matters
This filing serves as a routine update for investors, confirming the company's operational details and legal structure.
Risk Assessment
Risk Level: low — The filing is a routine 8-K without specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- February 29, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 100 – 740 McCurdy Road, Kelowna, BC Canada V1X 2P7 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting other events.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 29, 2024.
In which state is Lexaria Bioscience Corp. incorporated?
Lexaria Bioscience Corp. is incorporated in Nevada.
What is the principal executive office address for Lexaria Bioscience Corp.?
The principal executive office address is 100 – 740 McCurdy Road, Kelowna, BC Canada V1X 2P7.
What is the Commission File Number for Lexaria Bioscience Corp.?
The Commission File Number for Lexaria Bioscience Corp. is 001-39874.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-03-01 14:28:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
Filing Documents
- lxrp_8k.htm (8-K) — 23KB
- 0001640334-24-000328.txt ( ) — 167KB
- lxrp-20240229.xsd (EX-101.SCH) — 6KB
- lxrp-20240229_lab.xml (EX-101.LAB) — 17KB
- lxrp-20240229_cal.xml (EX-101.CAL) — 1KB
- lxrp-20240229_pre.xml (EX-101.PRE) — 13KB
- lxrp-20240229_def.xml (EX-101.DEF) — 6KB
- lxrp_8k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events On February 29, 2024, Lexaria Bioscience Corp. ("Lexaria") received a Study May Proceed letter from the U.S. Food and Drug Administration confirming the completion of its review of Lexaria's Investigational New Drug application and the determination that Lexaria may proceed with conducting its phase 1b hypertension clinical trial HYPER-H23-1 entitled A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension . Lexaria looks forward to commencing clinical trial HYPER-H23-1, subject to certain conditions including raising sufficient funding. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: March 1, 2024 3